Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges

BackgroundWith the introduction of novel therapies for inflammatory bowel diseases (IBD), 'treat-to-target' strategies are increasingly discussed to improve the short- and long-term outcomes in IBD patients. AimTo discuss opportunities and challenges of a treat-to-target approach in light of the current 'Selecting Therapeutic Targets in Inflammatory Bowel Disease' (STRIDE-II) consensus. MethodsThe 2021 update of STRIDE-II encompasses 13 evidence- and consensus-based recommendations for treat-to-target strategies in adults and children with IBD. We highlight the potential implications and limitations of these recommendations for clinical practice. ResultsSTRIDE-II provides valuable guidance for personalised IBD management. It reflects scientific progress as well as increased evidence of improved outcomes when more ambitious treatment goals such as mucosal healing are achieved. ConclusionsProspective studies, objective criteria for risk stratification, and better predictors of therapeutic response are needed to potentially render 'treating to target' more effective in the future.

Automated summary

This article discusses the opportunities and challenges of a treat-to-target approach in inflammatory bowel disease (IBD) patients, with a focus on the current "Selecting Therapeutic Targets in Inflammatory Bowel Disease" (STRIDE-II) consensus. The study results show that STRIDE-II provides valuable guidance for personalized IBD management and reflects increased evidence of improved outcomes when more ambitious treatment goals, such as mucosal healing, are achieved.